NCT04950322View on ClinicalTrials.gov

A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

737

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

May 20, 2024

Study Completion Date

October 1, 2025

Conditions
Gastric or Gastroesophageal Junction Cancer
Interventions
DRUG

SHR-1701、CAPOX

SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)

DRUG

Placebo、CAPOX

Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)

Trial Locations (1)

1000000

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY